Iza-bren

DRUG5 trials

Sponsors

Bristol-Myers Squibb, M.D. Anderson Cancer Center

Conditions

Breast NeoplasmsNon-Small Cell Lung CancerNon-small Cell Lung CancerUrothelial Cancer

Phase 1

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

RecruitingNCT07382726

M.D. Anderson Cancer CenterNon-small Cell Lung Cancer

Start: 2026-05-15End: 2029-12-24Target: 18Updated: 2026-08-11

Phase 2

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

RecruitingNCT06926868

Bristol-Myers SquibbBreast Neoplasms

Start: 2025-09-11End: 2030-05-15Target: 600Updated: 2026-08-10

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

RecruitingNCT07100080

Bristol-Myers SquibbNon-Small Cell Lung Cancer

Start: 2025-11-05End: 2030-11-15Target: 500Updated: 2026-08-25

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

RecruitingNCT07106762

Bristol-Myers SquibbUrothelial Cancer

Start: 2025-09-30End: 2033-11-18Target: 470Updated: 2026-07-29

Phase 3

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Not yet recruitingNCT07680790

Bristol-Myers SquibbNon-Small Cell Lung Cancer

Start: 2026-09-30End: 2031-12-30Target: 850Updated: 2026-08-24